Alterations of lung microbiota in lung transplant recipients with pneumocystis jirovecii pneumonia.
Pneumocystis jirovecii
Lung transplant
Metagenomic next-generation sequencing
Microbiota
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
14 Mar 2024
14 Mar 2024
Historique:
received:
21
01
2024
accepted:
04
03
2024
medline:
18
3
2024
pubmed:
15
3
2024
entrez:
15
3
2024
Statut:
epublish
Résumé
Increasing evidence revealed that lung microbiota dysbiosis was associated with pulmonary infection in lung transplant recipients (LTRs). Pneumocystis jirovecii (P. jirovecii) is an opportunistic fungal pathogen that frequently causes lethal pneumonia in LTRs. However, the lung microbiota in LTRs with P. jirovecii pneumonia (PJP) remains unknow. In this prospective observational study, we performed metagenomic next-generation sequencing (mNGS) on 72 bronchoalveolar lavage fluid (BALF) samples from 61 LTRs (20 with PJP, 22 with PJC, 19 time-matched stable LTRs, and 11 from LTRs after PJP recovery). We compared the lung microbiota composition of LTRs with and without P. jirovecii, and analyzed the related clinical variables. BALFs collected at the episode of PJP showed a more discrete distribution with a lower species diversity, and microbiota composition differed significantly compared to P. jirovecii colonization (PJC) and control group. Human gammaherpesvirus 4, Phreatobacter oligotrophus, and Pseudomonas balearica were the differential microbiota species between the PJP and the other two groups. The network analysis revealed that most species had a positive correlation, while P. jirovecii was correlated negatively with 10 species including Acinetobacter venetianus, Pseudomonas guariconensis, Paracandidimonas soli, Acinetobacter colistiniresistens, and Castellaniella defragrans, which were enriched in the control group. The microbiota composition and diversity of BALF after PJP recovery were also different from the PJP and control groups, while the main components of the PJP recovery similar to control group. Clinical variables including age, creatinine, total protein, albumin, IgG, neutrophil, lymphocyte, CD3 This study suggests that LTRs with PJP had altered lung microbiota compared to PJC, control, and after recovery groups. Furthermore, lung microbiota is related to age, renal function, nutritional and immune status in LTRs.
Sections du résumé
BACKGROUND
BACKGROUND
Increasing evidence revealed that lung microbiota dysbiosis was associated with pulmonary infection in lung transplant recipients (LTRs). Pneumocystis jirovecii (P. jirovecii) is an opportunistic fungal pathogen that frequently causes lethal pneumonia in LTRs. However, the lung microbiota in LTRs with P. jirovecii pneumonia (PJP) remains unknow.
METHODS
METHODS
In this prospective observational study, we performed metagenomic next-generation sequencing (mNGS) on 72 bronchoalveolar lavage fluid (BALF) samples from 61 LTRs (20 with PJP, 22 with PJC, 19 time-matched stable LTRs, and 11 from LTRs after PJP recovery). We compared the lung microbiota composition of LTRs with and without P. jirovecii, and analyzed the related clinical variables.
RESULTS
RESULTS
BALFs collected at the episode of PJP showed a more discrete distribution with a lower species diversity, and microbiota composition differed significantly compared to P. jirovecii colonization (PJC) and control group. Human gammaherpesvirus 4, Phreatobacter oligotrophus, and Pseudomonas balearica were the differential microbiota species between the PJP and the other two groups. The network analysis revealed that most species had a positive correlation, while P. jirovecii was correlated negatively with 10 species including Acinetobacter venetianus, Pseudomonas guariconensis, Paracandidimonas soli, Acinetobacter colistiniresistens, and Castellaniella defragrans, which were enriched in the control group. The microbiota composition and diversity of BALF after PJP recovery were also different from the PJP and control groups, while the main components of the PJP recovery similar to control group. Clinical variables including age, creatinine, total protein, albumin, IgG, neutrophil, lymphocyte, CD3
CONCLUSIONS
CONCLUSIONS
This study suggests that LTRs with PJP had altered lung microbiota compared to PJC, control, and after recovery groups. Furthermore, lung microbiota is related to age, renal function, nutritional and immune status in LTRs.
Identifiants
pubmed: 38486264
doi: 10.1186/s12931-024-02755-9
pii: 10.1186/s12931-024-02755-9
pmc: PMC10941442
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
125Subventions
Organisme : Zhongnanshan Medical Foundation of Guangdong Province
ID : ZNSA-2020013
Organisme : State Key Laboratory of Respiratory Disease/Guangzhou Institute of Respiratory Health/National Center for Respiratory Medicine
ID : SKLRHQN20205
Organisme : Specific Clinical Technology Project of Guangzhou City
ID : 2023C-TS10
Organisme : Natural Science Foundation of Guangdong Province
ID : 2022A1515012216
Organisme : Basic Research Program of Guangzhou Institute of Respiratory Health
ID : 202201020371
Informations de copyright
© 2024. The Author(s).
Références
Pharmacol Res. 2018 Aug;134:61-67
pubmed: 29890253
Front Cell Infect Microbiol. 2021 Sep 13;11:708827
pubmed: 34589441
Respir Res. 2021 Apr 23;22(1):118
pubmed: 33892717
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
J Genet Genomics. 2020 Oct 20;47(10):610-617
pubmed: 33388272
Microbiome. 2021 May 26;9(1):123
pubmed: 34039428
Front Cell Infect Microbiol. 2018 Jun 25;8:205
pubmed: 29988504
Am J Transplant. 2016 Jun;16(6):1766-78
pubmed: 26693965
Am J Respir Crit Care Med. 2012 Sep 15;186(6):536-45
pubmed: 22798321
J Infect Dis. 2010 Jul 15;202(2):302-12
pubmed: 20533880
PLoS One. 2013 Aug 02;8(8):e69969
pubmed: 23936365
Am J Transplant. 2021 Jul;21(7):2333-2340
pubmed: 33749996
Genome Res. 2019 May;29(5):831-842
pubmed: 30992304
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Lancet Respir Med. 2021 Jun;9(6):601-612
pubmed: 33460570
Eur J Clin Microbiol Infect Dis. 2021 Sep;40(9):1933-1942
pubmed: 33880744
Front Cell Infect Microbiol. 2020 Sep 29;10:571253
pubmed: 33117730
Ageing Res Rev. 2021 Mar;66:101235
pubmed: 33321253
Clin Infect Dis. 2019 Apr 8;68(8):1320-1326
pubmed: 30107568
Microorganisms. 2020 Jul 16;8(7):
pubmed: 32708647
J Heart Lung Transplant. 2020 Feb;39(2):176-183
pubmed: 31812487
Int J Chron Obstruct Pulmon Dis. 2015 Sep 29;10:2079-85
pubmed: 26491278
Lung. 2020 Dec;198(6):879-887
pubmed: 33169174
J Thorac Dis. 2016 Jun;8(6):1316-22
pubmed: 27293852
Clin Infect Dis. 2020 Sep 12;71(6):1367-1376
pubmed: 31802125
Thorax. 2022 Mar;77(3):283-291
pubmed: 34172558
J Heart Lung Transplant. 2021 Aug;40(8):733-744
pubmed: 34120840
BMC Genomics. 2014 Nov 27;15:1028
pubmed: 25428805
BMC Pulm Med. 2020 Mar 20;20(1):70
pubmed: 32197601
J Fungi (Basel). 2015 Sep 28;1(3):293-331
pubmed: 29376913
Front Immunol. 2021 Apr 12;12:652383
pubmed: 33912176
Am J Respir Crit Care Med. 2013 Nov 15;188(10):1224-31
pubmed: 23992479
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
J Allergy Clin Immunol. 2018 Feb;141(2):718-729.e7
pubmed: 28729000
Front Med. 2022 Jun;16(3):389-402
pubmed: 34302613
Int J Mol Sci. 2021 Oct 08;22(19):
pubmed: 34639212
J Infect Dis. 2022 Mar 2;225(5):868-880
pubmed: 34604908
Genome Biol. 2014;15(10):487
pubmed: 25344286
FEMS Microbiol Lett. 2013 Feb;339(1):57-65
pubmed: 23173619
Am J Respir Crit Care Med. 2013 Mar 15;187(6):640-7
pubmed: 23328523
J Infect. 2022 Aug;85(2):e44-e46
pubmed: 35659546
Annu Rev Physiol. 2016;78:481-504
pubmed: 26527186
J Infect. 2019 Feb;78(2):158-169
pubmed: 30149030
Am J Respir Crit Care Med. 2020 Mar 1;201(5):555-563
pubmed: 31973575
Am J Transplant. 2013 Mar;13 Suppl 4:272-9
pubmed: 23465020